Product Images Losartan Potassium 25 Mg

This is a medical research report that displays the results of patients treated with Atenolol and Losartan Potassium drugs. The report states the adjusted risk reduction percentage, which is 13%, with a p-value of 0.021. The horizontal axis shows different study months (from 6 to 66) while there's no clear information about the vertical axis.*

This text is not available to generate a useful description as it contains incomplete and unclear information.*

This is a tabular representation of the results of a study comparing the effectiveness of Losartan and Atenolol in reducing the incidence of Primary Composite Stroke among patients. The table shows the number of patients who experienced the outcome under consideration, the rate of the outcome, the hazard ratio, and 95% confidence interval for Losartan and Atenolol treatments. The patients are also categorized based on age, gender, race, history of CVD, diabetes, and other factors. The details of the study are not available.*

The data represents the percentage of patients who experienced an event, along with the associated risk reduction percentage and p-value. There is no information on what type of event is being measured, and the numbers 40 and 20 do not provide any context.*

This is a product description for LoF' LiSharan rorassiun, which comes in a 30 tablet container (Product No. 6394-0). The recommended storage temperature is 7°C.*